Overall, however, the amount of p52 detected in both healthy individuals and MS patients was low, suggesting that the non-canonical pathway may be less dominant than the canonical pathway in the altered NF-κB pathway activation seen in MS patients. This evidence concerns the gene NFKB2 and myeloid sarcoma.